Skip to content

NMN administration in preterm children

A pilot study on the safety and effectiveness of NMN in children born preterm

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031250189
Enrollment
10
Registered
2025-06-27
Start date
2025-06-27
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm infants

Interventions

NMN 125mg (2 tablets at a time) will be orally administered once daily after dinner for 12 weeks.

Sponsors

Shoji Hiromichi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Preterm infants less than 32 weeks of gestation or very low birth weight infants less than 1,500g 2) Children aged 6 years or older and 9 years or younger at the time of obtaining consent 3) Children receiving outpatient care 4) Children attending regular nursery schools, kindergartens, or elementary schools 5) Children who have written consent from a legal representative 6) Children who the principal investigator (subinvestigator) judges to be able to appropriately evaluate the efficacy and safety of this study after considering the inclusion and exclusion criteria

Exclusion criteria

Exclusion criteria: 1) Children with mental or motor development problems who are unable to safely take the chewable tablets used 2) Children who are unable to take chewable tablets 3) Children taking NMN as a supplement 4) Children undergoing treatment for other diseases 5) Children who the principal investigator (subinvestigator) considers inappropriate as study subjects

Design outcomes

Primary

MeasureTime frame
Safety evaluation (occurrence of side effects in children related to NMN intake and duration of clinical test results)

Secondary

MeasureTime frame
1) Blood NAD concentration (Changes from before administration to the end of NMN administration) 2) Changes in body size (BMI, obesity level, fat mass, body fat percentage, fat-free mass, lean mass index) (Changes from before administration to the end of NMN administration) 3) Insulin resistance evaluation (blood glucose level, insulin level, HOMA-IR) (Changes from before administration to the end of NMN administration) 4) Urinary oxidative stress marker (8-OHdG level) (Changes from before administration to the end of NMN administration)

Contacts

Public ContactHiromichi Shoji

Juntendo University, Juntendo hospital

hshoji@juntendo.ac.jp+81-338133111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026